NDC product
XPHOZAH 10 mg
NDC 73154-110 · Ardelyx, Inc.
Key facts
| Product NDC | 73154-110 |
|---|---|
| Proprietary name | XPHOZAH 10 mg |
| Nonproprietary name | Tenapanor |
| Substances | TENAPANOR HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Ardelyx, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA213931 |
| Pharmacologic classes | Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], Sodium-Hydrogen Exchanger 3 Inhibitor [EPC], Sodium-Hydrogen Exchanger 3 Inhibitors [MoA] |
| Marketing start | Oct 17, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: